Bernabe-Ortiz Antonio, Carrillo-Larco Rodrigo M
Universidad Cientifica del Sur, Lima, Peru.
Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
Wellcome Open Res. 2024 Aug 19;8:287. doi: 10.12688/wellcomeopenres.19498.4. eCollection 2023.
The prevalence of overweight and obesity has increased fastest in low- and middle-income countries in the last decades. Together with this rising prevalence, pharmacological and surgical interventions for obesity have emerged. How many people need these treatments is unknown. We quantified the prevalence of people in need of pharmacological and surgical treatment for obesity in Peru between 2014 and 2022.
Repeated cross-sectional analysis of national health surveys in Peru was conducted. Eligibility for pharmacological treatment for obesity was: body mass index (BMI) ≥30 kg/m or BMI ≥27 kg/m alongside type 2 diabetes or hypertension (self-reported). Eligibility for bariatric surgery were BMI ≥40 kg/m or BMI between 35 to 39.9 kg/m linked to weight-related health problems. We used Poisson regressions to identify associated factors with eligibility for obesity management.
Across years, 260,131 people (mean age 44.0 and 54.5% were women) were studied, 66,629 (27.7%; 95% CI: 27.4% - 28.1%) were eligible for obesity medication, and 5,263 (2.5%; 95% CI: 2.4% - 2.6%) were eligible for bariatric surgery. Female sex, older age, higher socioeconomic level and study year were associated with higher probability of eligibility for both obesity medication and bariatric surgery.
Eligibility for obesity management has increased over time in Peru. There is a need to strengthen policies to tackle overweight and obesity in Peru, acknowledging that some individuals may benefit from pharmacological and surgical interventions.
在过去几十年中，低收入和中等收入国家超重和肥胖的患病率增长最快。随着患病率的上升，针对肥胖的药物和手术干预措施也应运而生。尚不清楚有多少人需要这些治疗。我们对2014年至2022年期间秘鲁需要药物和手术治疗肥胖症的人群患病率进行了量化。
对秘鲁全国健康调查进行重复横断面分析。肥胖药物治疗的 eligibility标准为：体重指数（BMI）≥30 kg/m² 或BMI≥27 kg/m² 且伴有2型糖尿病或高血压（自我报告）。减肥手术的eligibility标准为BMI≥40 kg/m² 或BMI在35至39.9 kg/m² 之间且伴有与体重相关的健康问题。我们使用泊松回归来确定与肥胖管理eligibility相关的因素。
多年来，共研究了260,131人（平均年龄44.0岁，54.5%为女性），其中66,629人（27.7%；95%置信区间：27.4% - 28.1%）符合肥胖药物治疗eligibility标准，5,263人（2.5%；95%置信区间：2.4% - 2.6%）符合减肥手术eligibility标准。女性、年龄较大、社会经济水平较高和研究年份与肥胖药物治疗和减肥手术eligibility的较高概率相关。
秘鲁肥胖管理的eligibility随时间推移有所增加。秘鲁需要加强应对超重和肥胖的政策，认识到一些人可能从药物和手术干预中受益。
